Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Cambridge, USA
5 Cambridge Center, Floor 2
Cambridge, MA, 02142
USA

People

CFO
President & CEO & Board Director
Board Member and CEO
Board Director
Board Director
Board Director
Board of Directors
Chief Medical Officer
Show All People

Funding

TOTAL $132M
FUNDING TOTAL $132M
Series A, 9/2006
Atlas Venture
GreatPoint Ventures
$5.18M
Series B, 3/2010
Atlas Venture
Third Rock Ventures
GreatPoint Ventures
$28M
Series C, 7/2011
Atlas Venture
Third Rock Ventures
$33M
Series D, 12/2012
Alta Partners
Atlas Venture
Third Rock Ventures
$21M
Series E, 12/2013
RA Capital Management
Brookside Capital
Venrock
Alta Partners
$45M
DEBT TOTAL $3M
Debt, 8/2012
$3M

Tags

Zafgen

Zafgen is the world’s first biopharmaceutical company dedicated to developing novel obesity therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean, healthy state. Adipose tissue (fat) is composed primarily of cells that store unused calories for later use. The balance between how the body stores excess calories and later accesses these depots when required plays a critical role in determining the overall size of the fat tissue, and therefore, an individual’s weight. Zafgen’s groundbreaking approach targets obesity at its biological foundation by safely restoring the balance of fat metabolism, driving the loss of fat and a return to a more healthy body weight. Zafgen’s leadership and scientific advisors include the leading experts in obesity, metabolic disorders and medicinal chemistry. Founded in 2005, the company is located in Cambridge, Massachusetts.

Recent Milestones

Videos

Screenshots

Zafgen screenshot
Above: Zafgen
Uploaded: 3/13/10

Sources

  1. EDGAR [edit]
  2. ZafGen, Inc.: Series B $8.1M (onbiovc.com) [edit]
  3. Zafgen Secures $33 Million Series C Financing (eon.businesswire.com) [edit]
  4. Zafgen raises $3M for weight-loss drug (masshightech.com) [edit]
  5. Obesity drug developer Zafgen raises $21M (masshightech.com) [edit]
  6. Zafgen Secures $45M in Series E Equity Financing (finsmes.com) [edit]
  7. Zafgen's obesity drug shows promise in early study (masshightech.com) [edit]
Edit This Page
Last Edited 1/29/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy